HDL 2 Particles are associated with hyperglycaemia, lower PON1 activity and oxidative stress in type 2 diabetes mellitus patients

Clinical Biochemistry

Volumn 43, Issue 15, 2010, Pages 1230-1235

  Stefanović, Aleksandra ^a   Kotur Stevuljević, Jelena ^a   Spasić, Slavica ^a   Vekić, Jelena ^a   Zeljković, Aleksandra ^a   Spasojević Kalimanovska, Vesna ^a   Jelić Ivanović, Zorana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Diabetes mellitus type 2; HDL 2 particles; Oxidative stress; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PARTICLE SIZE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ARYLDIALKYLPHOSPHATASE; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; LIPOPROTEINS, HDL2; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARTICLE SIZE; PHENOTYPE; STATISTICS, NONPARAMETRIC;

EID: 77956719446     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.08.005     Document Type: Article

References (37)

1. Song S.H. Review: early-onset type 2 diabetes mellitus: a condition with elevated cardiovascular risk. Br J Diab & Vascular Dis 2008, 8:61-65.
2. Standards of Medical Care for Patients With Diabetes Mellitus. Diabetes Care 2003; 26: S33-S50.
3. Chisolm G.M., Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 2000, 28(12):1815-1826.
4. Galasseti P., Pontello A. Dietary effects on oxidation of low-density lipoprotein and atherogenesis. Curr Atheroscler Rep 2006, 8(6):523-529.
5. Assmann G., Gotto A.M. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004, 109:III-8-III-14.
6. Kontush A., Faria E.C., Chantepie S., Chapman M.J. Antioxidative activity of hdl particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties. Arterioscler Thromb Vasc Biol 2004, 24:526-533.
7. Skinner E.R. High-density lipoprotein subclasses. Curr Opin Lipidol 1994, 5(3):241-247.
8. Kontush A., Chantepie S., Chapman M.J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23:1881-1888.
9. Ferretti G., Bacchetti T., Negre-Salvayre A., Salvayre R., Dousset N., Curatola G. Structural modifications of HDL and functional consequences. Atherosclerosis 2006, 184(1):1-7.
10. Gowri M.S., Van der Westhuyzen D.R., Bridges S.R., Anderson J.W. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999, 19:2226-2233.
11. National Diabetes Data Group Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979, 28:1039-1057.
12. Franz M.J., Bantle J.P., Beebe C.A., et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diab Care 2003, 26(suppl):S51-S61.
13. Jones C.S., Marshall S.M., Bilous R.W. Diabetic nephropathy. International Textbook of Diabetes Mellitus 2004, 1220. Wiley, UK. 3rd ed. R.A. DeFronzo, E. Ferrannini, H. Keen, P. Zimmet (Eds.).
14. The Expert Panel Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). Final report. Circulation 2002; 106: 3143-421.
15. Auclar C., Voisin E. Nitroblue tetrazolium reduction. CRC Handbook of Methods for Oxygen Radical research 1985, 123-132. Fla: CRC Press, Boca Raton. R.A. Greenworld (Ed.).
16. Misra H.P., Fridovich I. Chemistry and metabolism of substances of low molecular weight: the role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972, 247:3170-3175.
17. G.l.Ellman Tissue sulfhydril groups. Arc Biochem Biophys 1952, 82:70-77.
18. Richter R.J., Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999, 9(6):745-753.
19. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993, 52(3):598-608.
20. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995, 96(6):3005-3008.
21. Rainwater D.L., Moore P.H., Shelledy W.R., Dyer T.D., Slifer S.H. Characterization of a composite gradient gel for the electrophoretic separation of lipoproteins. J Lipid Res 1997, 38:1261-1266.
22. Vekic J., Topic A., Zeljkovic A., Jelic-Ivanovic Z., Spasojevic-Kalimanovska V. LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. Clin Biochem 2007, 40(5-6):310-316.
23. Blanche P.J., Gong E.L., Forte T.M. Nichols AV.Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981, 665(3):408-419.
24. Bland J.M., Altman D.G. Statistics notes: transformations, means and confidence intervals. BMJ 1996, 312:1079-1080.
25. Cavallero E., Dachet C., Neufcour D., Wirquin E., Mathe D.B., Jacotot B. Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels. Metabolism 1994, 43(3):270-278.
26. Taskinen M.R. Diabetic dyslipidemia. Atheroscler Suppl 2002, 3(1):47-51.
27. Elchebly M., Porokhov B., Pulcini T., Berthezene F., Ponsin G. Alterations in composition and concentration of lipoproteins and elevated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus (NIDDM). Atherosclerosis 1996, 123(1-2):93-101.
28. Krauss R.M. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994, 5(5):339-349.
29. Hodge Allison M., Jenkins Alicia J., English Dallas R., Kerin O'Dea, Giles Graham G. NMR-determined lipoprotein subclass profile predicts type 2 diabetes. Diab Res Clin Pract 2009, 83:132-139.
30. Madamanchi N.R., Vendrov A., Runge M.S. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005, 25:29-38.
31. Stephens J.W., Gable D.R., Hurel S.J., Miller G.J., Cooper J.A., Humphries S.E. Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males. Clin Chem 2006, 52:446-452.
32. Mackness M.I., Arrol S., Abbott C., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104(1-2):129-135.
33. Mackness B., Durrington P.N., Abuashia B., Boulton A.J., Mackness M.I. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci 2000, 98(3):355-363.
34. Sanghera D.K., Aston C.E., Saha N., Kamboh M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998, 62(1):36-44.
35. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995, 15:1812-1818.
36. Hedrick C.C., Thorpe S.R., Fu M.X., Harper C.M., Yoo J., Kim S.M., et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000, 43(3):312-320.
37. Ferretti G., Bacchetti T., Busni D., Rabini R.A., Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 2004, 89:2957-2962.